The latest issue of NPS RADAR
features a review of dapagliflozin
(Forxiga) and canagliflozin
(Invokana) which are listed on the
PBS from Dec 1.
These are the first PBS-listed
medicines from a new class of oral
anti-diabetics, the sodium-glucose
co-transporter 2 (SGLT2) inhibitors.
December’s NPS RADAR
also includes in-depth reviews
of fluticasone propionate
with eformoterol fumarate
(Flutiform) for asthma,
olmesartan with amlodipine and
hydrochlorothiazide (Sevikar HCT),
a triple fixed-dose combination
for hypertension and Ivabradine
(Coralan) for chronic heart failure.
Go to www.nps.org.au/radar for
details of the reviews.The above article was sent to subscribers in Pharmacy Daily's issue from 04 Dec 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Dec 13
AUSTRALIA needs more pharmacists than ever, in the face of an ageing population and rising healthcare demands, according to the Pharmaceutical Society of Australia (PSA).
INTERN pharmacists from Monash University are set to join Victoria’s immunisation workforce under a new Secretary Approval by the Victorian Health Department.
VIRTUAL care delivered through telephone or video conference has now embedded itself as a core component of healthcare delivery in NSW, new market reports released today have revealed.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.